04:53 PM EST, 11/08/2024 (MT Newswires) -- Fate Therapeutics ( FATE ) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.

The data "support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells," Bob Valamehr, head of research and development at Fate, said in a statement.

Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.

FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel "Sword & Shield" technology "to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors," the company said.

Price: 2.47, Change: +0.05, Percent Change: +2.07